Commentaries
Vol. 2 No. 1 (2023)
How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 11 November 2022
Accepted: 7 December 2022
Accepted: 7 December 2022
1070
Views
427
Downloads
Authors
With ageing of the population, both the risks of cardiovascular disease (CVD) and cancer are increasing worldwide, and the risk factors (e.g. obesity, diabetes) are often shared between the two conditions. Thus, more subjects will also develop the two illnesses concurrently [...].
Downloads
Download data is not yet available.
Citations
Willems RAL, Winckers K, Biesmans C, et al. Evolving data on cardiovascular complications in cancer. Thromb Res 2022;213:S87-S94. DOI: https://doi.org/10.1016/j.thromres.2022.01.003
Donnellan E, Khorana AA. Cancer and venous thromboembolic disease: a review. Oncologist 2017;22:199-2. DOI: https://doi.org/10.1634/theoncologist.2016-0214
Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926-38. DOI: https://doi.org/10.1016/j.jacc.2017.06.047
Navi BB, Reiner AS, Kamel H, et al. Arterial thromboembolic events preceding the diagnosis of cancer in older persons. Blood 2019;133:781-9. DOI: https://doi.org/10.1182/blood-2018-06-860874
Falanga A, Leader A, Ambaglio C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. HemaSphere 2022;6:e750. DOI: https://doi.org/10.1097/HS9.0000000000000750
How to Cite
1.
Falanga A et al. How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines. Bleeding Thromb Vasc Biol [Internet]. 2023 Jan. 27 [cited 2026 Apr. 14];2(1). Available from: https://www.btvb.org/btvb/article/view/60
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- PO64 | A silent hemorrhage in the immuno-thrombotic chaos of antiphospholipid syndrome , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Alice Lipari, Esmeralda Capristo, Antonietta Ferretti, Erica De Candia, Anticoagulation in obese patients: challenges and strategies , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Emanuele Valeriani, Arianna Pannunzio, Danilo Menichelli, Domenico Prisco, Walter Ageno, Daniele Pastori, Pasquale Pignatelli, Executive summary of the SISET position paper on the management of antithrombotic therapy in left ventricular thrombus , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- PO92 | Challenging management of portal vein thrombosis in a cirrhotic patient on hormone therapy after breast cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Roger Lijnen, Désiré Collen, The key to fibrinolysis and thrombolysis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 3 (2025)
- Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth, Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Società Italiana di Emostasi e Trombosi, PO49 | PROPHYLACTIC ANTICOAGULATION DECISIONS IN HIGH-RISK PATIENTS RECEIVING CANCER-DIRECTED THERAPY: ANALYSIS OF THE VERMONT METHOD , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO39 | RISK OF VENOUS THROMBOEMBOLISM ASSOCIATED WITH PERIPHERALLY INSERTED CENTRAL CATHETERS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY: A REAL-WORLD SINGLE-CENTRE EXPERIENCE , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
- Società Italiana di Emostasi e Trombosi, PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER , Bleeding, Thrombosis and Vascular Biology: Vol. 5 No. s1 (2026)
1-10 of 341
Next
You may also start an advanced similarity search for this article.
